AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18222194 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost
Number of subjects: 410
Study 18222194 — intervention group
Group type: EXPERIMENTAL
Intervention: Travoprost
Number of subjects: 410
Study 18222194 — intervention group
Group type: COMPARATOR
Intervention: Overall
Number of subjects: 410
Study 18222194 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost vs Travoprost
Number of subjects: 410
Study 16779849 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone positioning
Number of subjects: 19
Study 16779849 — intervention group
Group type: COMPARATOR
Intervention: Supine positioning
Number of subjects: 19
Study 14579028 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonoperative therapy, including modification of sports and recreational activities
Number of subjects: 0
Study 14579028 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative options such as resecting arthroscopic procedures, repair of damaged articular cartilage, osteotomy, and unicompartmental knee arthroplasty
Number of subjects: 0
Study 14579028 — intervention group
Group type: COMPARATOR
Intervention: Control group not explicitly mentioned
Number of subjects: 0
Study 10862585 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous flecainide (n = 39)
Number of subjects: 79
Study 10862585 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral flecainide (n = 40)
Number of subjects: 79
Study 8936895 — intervention group
Group type: COMPARATOR
Intervention: LAX
Number of subjects: 44
Study 8936895 — intervention group
Group type: EXPERIMENTAL
Intervention: ETT
Number of subjects: 44
Study 8936895 — intervention group
Group type: EXPERIMENTAL
Intervention: BF
Number of subjects: 44
Study 1420057 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg of Diamox Sustets (acetazolamide) 1 hour preoperatively
Number of subjects: 36
Study 1420057 — intervention group
Group type: EXPERIMENTAL
Intervention: Peroperative intracameral Miochol (acetylcholine)
Number of subjects: 36
Study 1420057 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment of acetazolamide and acetylcholine
Number of subjects: 36
Study 6536517 — intervention group
Group type: EXPERIMENTAL
Intervention: Gases humidified and heated to 37 degrees C
Number of subjects: 30
Study 6536517 — intervention group
Group type: EXPERIMENTAL
Intervention: Gases humidified and heated to 40 degrees C
Number of subjects: 30
Study 6536517 — intervention group
Group type: COMPARATOR
Intervention: Control group with anaesthetic gases humidified by a sponge heat and moisture exchanger
Number of subjects: 30
Study 31063198 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk microbiome
Number of subjects: 21
Study 31063198 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant oral microbiome
Number of subjects: 21
Study 31063198 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal and infant fecal microbiomes
Number of subjects: 21
Study 31063198 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbial community structures
Number of subjects: 21
Study 31063198 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex microbial interactions
Number of subjects: 21
Study 30092157 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 IU/day vitamin D (cholecalciferol, Calcirol® sachet) administered as a stat dose of 90,000 IU every three months.
Number of subjects: 60
Study 30092157 — intervention group
Group type: COMPARATOR
Intervention: 400 IU/day vitamin D (cholecalciferol) administered as a stat dose of 36,000 IU every three months.
Number of subjects: 60
Study 27485377 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian adaptive patient enrollment restriction (BAPER) approach
Number of subjects: 0
Study 27485377 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-parameter change-point model
Number of subjects: 0
Study 24770498 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical potassium hydroxide therapy
Number of subjects: 48
Study 24770498 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy
Number of subjects: 48
Study 21458108 — intervention group
Group type: EXPERIMENTAL
Intervention: Circumferential subannular grafting (group A)
Number of subjects: 63
Study 21458108 — intervention group
Group type: COMPARATOR
Intervention: Conventional underlay tympanoplasty (group B)
Number of subjects: 63
Study 20458465 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical tibial nerve stimulation (TTNS) in addition to standard therapy (bladder retraining and pelvic floor muscle exercises)
Number of subjects: 51
Study 20458465 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (bladder retraining and pelvic floor muscle exercises)
Number of subjects: 51
Study 17188941 — intervention group
Group type: EXPERIMENTAL
Intervention: Sample size calculation considering center effect
Number of subjects: 0
Study 16390031 — intervention group
Group type: EXPERIMENTAL
Intervention: Tauc‐FP
Number of subjects: 40
Study 16390031 — intervention group
Group type: EXPERIMENTAL
Intervention: MUGA
Number of subjects: 40
Study 16390031 — intervention group
Group type: EXPERIMENTAL
Intervention: MIBI‐FP
Number of subjects: 40
Study 16390031 — intervention group
Group type: EXPERIMENTAL
Intervention: MIBI‐gFP
Number of subjects: 40
Study 16390031 — intervention group
Group type: EXPERIMENTAL
Intervention: GSPECT
Number of subjects: 40
Study 12483094 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% once daily for 8 weeks
Number of subjects: 48
Study 12483094 — intervention group
Group type: COMPARATOR
Intervention: Isopropyl unoprostone 0.12% twice daily for 8 weeks
Number of subjects: 48
Study 12483094 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost
Number of subjects: 48
Study 12483094 — intervention group
Group type: COMPARATOR
Intervention: Isopropyl unoprostone
Number of subjects: 48
Study 10682558 — intervention group
Group type: EXPERIMENTAL
Intervention: Epimedium compound granules
Number of subjects: 120
Study 10682558 — intervention group
Group type: COMPARATOR
Intervention: Su‐Guan‐Bian (Control)
Number of subjects: 120
Study 7781793 — intervention group
Group type: EXPERIMENTAL
Intervention: HemeSelect at 1:8 dilution
Number of subjects: 1489
Study 7781793 — intervention group
Group type: EXPERIMENTAL
Intervention: HemeSelect at 1:16 dilution
Number of subjects: 1489
Study 7781793 — intervention group
Group type: EXPERIMENTAL
Intervention: HemeSelect at 1:32 dilution
Number of subjects: 1489
Study 7781793 — intervention group
Group type: EXPERIMENTAL
Intervention: HemeSelect at 1:64 dilution
Number of subjects: 1489
Study 7781793 — intervention group
Group type: EXPERIMENTAL
Intervention: HemeSelect at 1:128 dilution
Number of subjects: 1489
Study 7781793 — intervention group
Group type: COMPARATOR
Intervention: Haemoccult
Number of subjects: 1489
Study 2650730 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfuzosin 5 mg
Number of subjects: 10
Study 2650730 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 589554 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy including vincristine at 3-week intervals
Number of subjects: 462
Study 589554 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine-prednisone
Number of subjects: 462
Study 589554 — intervention group
Group type: COMPARATOR
Intervention: Melphalan-cyclophosphamide-BCNU-prednisone
Number of subjects: 462
Study 589554 — intervention group
Group type: COMPARATOR
Intervention: Other therapies or no therapy
Number of subjects: 462
Study 31882232 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised nutritional support intervention
Number of subjects: 2028
Study 31882232 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control group)
Number of subjects: 2028
Study 31882232 — intervention group
Group type: EXPERIMENTAL
Intervention: NRS score increase
Number of subjects: 2028
Study 31576450 — intervention group
Group type: EXPERIMENTAL
Intervention: PFMT + WL
Number of subjects: 22
Study 27632835 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained traction (ST)
Number of subjects: 20
Study 27632835 — intervention group
Group type: EXPERIMENTAL
Intervention: Oscillatory traction (OT)
Number of subjects: 20
Study 27632835 — intervention group
Group type: COMPARATOR
Intervention: Sham condition
Number of subjects: 20
Study 26179284 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (a widely available food supplement with a low risk safety profile)
Number of subjects: 0
Study 23663287 — intervention group
Group type: EXPERIMENTAL
Intervention: General SAPS3
Number of subjects: 4617
Study 23663287 — intervention group
Group type: EXPERIMENTAL
Intervention: Australasia SAPS3
Number of subjects: 4617
Study 23663287 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized SAPS3 for Korean ICU patients
Number of subjects: 4617
Study 23663287 — intervention group
Group type: COMPARATOR
Intervention: ICU mortality
Number of subjects: 4617
Study 23663287 — intervention group
Group type: COMPARATOR
Intervention: Hospital mortality
Number of subjects: 4617
Study 21311504 — intervention group
Group type: EXPERIMENTAL
Intervention: 60,000 IU monthly oral vitamin D(3) for 16 weeks
Number of subjects: 57
Study 21311504 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 16 weeks
Number of subjects: 57
Study 18757052 — intervention group
Group type: EXPERIMENTAL
Intervention: Familiarity based on activated representations in long-term memory
Number of subjects: 0
Study 18757052 — intervention group
Group type: EXPERIMENTAL
Intervention: Recollection accessing feature bindings
Number of subjects: 0
Study 18757052 — intervention group
Group type: EXPERIMENTAL
Intervention: Familiarity based on matching letters
Number of subjects: 0
Study 18757052 — intervention group
Group type: EXPERIMENTAL
Intervention: Recollection using binding information
Number of subjects: 0
Study 17227200 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicondition care management system
Number of subjects: 120
Study 15652899 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated isoflavones (114 mg daily for 3 months)
Number of subjects: 64
Study 15652899 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 12476384 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia with ropivacaine and sufentanil
Number of subjects: 20
Study 9689393 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium (0.09 mg kg‐1, n = 10)
Number of subjects: 40
Study 9689393 — intervention group
Group type: EXPERIMENTAL
Intervention: Pipecuronium (0.08 mg kg‐1, n = 10)
Number of subjects: 40
Study 9689393 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium (0.6 mg kg‐1, n = 10)
Number of subjects: 40
Study 9689393 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium (0.1 mg kg‐1, n = 10)
Number of subjects: 40
Study 7857439 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracervical prostaglandin E2 (PGE2) 0.5 mg
Number of subjects: 52
Study 7857439 — intervention group
Group type: COMPARATOR
Intervention: Conservative management (expectant management for 24 hours)
Number of subjects: 52
Study 7857439 — intervention group
Group type: COMPARATOR
Intervention: Intravenous oxytocin (if labor not established)
Number of subjects: 52
Study 2678652 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg tolfenamic acid
Number of subjects: 149
Study 2678652 — intervention group
Group type: COMPARATOR
Intervention: 1 g paracetamol
Number of subjects: 149
Study 4717848 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal
Number of subjects: 0
Study 4717848 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine
Number of subjects: 0
Study 4717848 — intervention group
Group type: COMPARATOR
Intervention: Activated charcoal or cholestyramine
Number of subjects: 0
Study 30779718 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients enrolled from 2005 to 2010
Number of subjects: 5159
Study 30779718 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients enrolled after 2010
Number of subjects: 5159
Study 30779718 — intervention group
Group type: COMPARATOR
Intervention: Crude mortality rate in 1996
Number of subjects: 5159
Study 30779718 — intervention group
Group type: COMPARATOR
Intervention: Crude mortality rate in 2013
Number of subjects: 5159
Study 30779718 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily fluid balance, tidal volume, plateau pressure, positive end-expiratory pressure
Number of subjects: 5159
Study 28057550 — intervention group
Group type: EXPERIMENTAL
Intervention: LBPT 225mg
Number of subjects: 85
Study 28057550 — intervention group
Group type: EXPERIMENTAL
Intervention: LBPT 300mg
Number of subjects: 85
Study 28057550 — intervention group
Group type: EXPERIMENTAL
Intervention: LBPT 400mg
Number of subjects: 85
Study 28057550 — intervention group
Group type: EXPERIMENTAL
Intervention: LBPT 500mg
Number of subjects: 85
Study 28057550 — intervention group
Group type: EXPERIMENTAL
Intervention: LBPT under fasting conditions
Number of subjects: 85
Study 28057550 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 25925557 — intervention group
Group type: EXPERIMENTAL
Intervention: Affected eyes with CRVO
Number of subjects: 83
Study 25925557 — intervention group
Group type: EXPERIMENTAL
Intervention: Affected eyes with BRVO
Number of subjects: 83
Study 25925557 — intervention group
Group type: COMPARATOR
Intervention: Control eyes
Number of subjects: 83
Study 23996292 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg ketoprofen in 4.4 g transfersome gel (IDEA-033)
Number of subjects: 555
Study 23996292 — intervention group
Group type: COMPARATOR
Intervention: 4.4 g ketoprofen-free vehicle (TDT 064)
Number of subjects: 555
Study 21756276 — intervention group
Group type: COMPARATOR
Intervention: Transrectal ultrasonography-guided systematic bioptic sampling
Number of subjects: 300
Study 21756276 — intervention group
Group type: EXPERIMENTAL
Intervention: Colour Doppler ultrasonography
Number of subjects: 300
Study 21756276 — intervention group
Group type: EXPERIMENTAL
Intervention: Colour Doppler ultrasonography with SonoVue™ contrast agent
Number of subjects: 300
Study 19805753 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopic surveillance (n = 1543)
Number of subjects: 26
Study 19805753 — intervention group
Group type: COMPARATOR
Intervention: Discharged following colonoscopy (n = 183)
Number of subjects: 26
Study 19805753 — intervention group
Group type: COMPARATOR
Intervention: No polyps (n = 26,573)
Number of subjects: 26
Study 19805753 — intervention group
Group type: COMPARATOR
Intervention: Lower-risk polyps removed at FS (n = 7401)
Number of subjects: 26
Study 16995327 — intervention group
Group type: EXPERIMENTAL
Intervention: Valdecoxib (20 mg, o.d.)
Number of subjects: 15
Study 16995327 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib (25 mg, o.d.)
Number of subjects: 15
Study 16995327 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol (50 mg)
Number of subjects: 15
Study 12752651 — intervention group
Group type: EXPERIMENTAL
Intervention: Herofill Soft-Core system
Number of subjects: 64
Study 12752651 — intervention group
Group type: COMPARATOR
Intervention: Lateral condensation
Number of subjects: 64
Study 12752651 — intervention group
Group type: COMPARATOR
Intervention: Thermomechanical compaction
Number of subjects: 64
Study 12734781 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 570
Study 12734781 — intervention group
Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 570
Study 12734781 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine (overweight subgroup)
Number of subjects: 570
Study 12734781 — intervention group
Group type: COMPARATOR
Intervention: NPH insulin (overweight subgroup)
Number of subjects: 570
Study 9876706 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia (PCA)
Number of subjects: 72
Study 9876706 — intervention group
Group type: COMPARATOR
Intervention: Intermittent intramuscular injection of morphine
Number of subjects: 72
Study 8779655 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant vitamins and related micronutrients
Number of subjects: 0
Study 8779655 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene, vitamin C, and vitamin E
Number of subjects: 0
Study 8779655 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinoids
Number of subjects: 0
Study 8779655 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary advice or intervention
Number of subjects: 0
Study 2171616 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (4 mg)
Number of subjects: 8
Study 2171616 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (10 mg)
Number of subjects: 8
Study 2171616 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 461072 — intervention group
Group type: EXPERIMENTAL
Intervention: Orientation recognition task with two stimuli
Number of subjects: 2
Study 31004689 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance training (exercised twice a week for 12 weeks)
Number of subjects: 14
Study 31004689 — intervention group
Group type: COMPARATOR
Intervention: Blind relaxation group (control)
Number of subjects: 14
Study 29390298 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (Group S)
Number of subjects: 44
Study 29390298 — intervention group
Group type: COMPARATOR
Intervention: Ketamine (Group K)
Number of subjects: 44
Study 25586727 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen concentrate (2 g or equivalent)
Number of subjects: 249
Study 25586727 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 249
Study 24099859 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 0
Study 24099859 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21678430 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol word primes
Number of subjects: 104
Study 21678430 — intervention group
Group type: COMPARATOR
Intervention: Nonalcohol word primes
Number of subjects: 104
Study 21678430 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol word primes with aggressive target
Number of subjects: 104
Study 21678430 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual presentation of alcoholic beverage images
Number of subjects: 104
Study 21678430 — intervention group
Group type: COMPARATOR
Intervention: Visual presentation of nonalcoholic beverage images
Number of subjects: 104
Study 19549431 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide 80 microg twice daily (CIC80 b.i.d.)
Number of subjects: 446
Study 19549431 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide 160 microg once daily (CIC160 q.d.)
Number of subjects: 446
Study 19549431 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 446
Study 19549431 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide treatments (CIC80 b.i.d. and CIC160 q.d.)
Number of subjects: 446
Study 19549431 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 446
Study 16428009 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised easy-to-read immunization pamphlets
Number of subjects: 37
Study 16428009 — intervention group
Group type: COMPARATOR
Intervention: Standard vaccine information sheets
Number of subjects: 37
Study 14745855 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver skill‐building interventions
Number of subjects: 0
Study 14745855 — intervention group
Group type: COMPARATOR
Intervention: Information/support interventions
Number of subjects: 0
Study 11348454 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.025% all‐trans retinoic acid
Number of subjects: 8
Study 11348454 — intervention group
Group type: COMPARATOR
Intervention: 5% sodium lauryl sulfate (irritant control)
Number of subjects: 8
Study 11348454 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 8
Study 11348454 — intervention group
Group type: COMPARATOR
Intervention: Control area (occluded)
Number of subjects: 8
Study 11348454 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term (192 wk) all‐trans retinoic acid treatment (n = 5)
Number of subjects: 8
Study 9237602 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta Blockers (BB)
Number of subjects: 210
Study 9237602 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 210
Study 8431375 — intervention group
Group type: EXPERIMENTAL
Intervention: CMF
Number of subjects: 40
Study 8431375 — intervention group
Group type: COMPARATOR
Intervention: Epirubicin
Number of subjects: 40
Study 29946873 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot compress with Chinese herbal salt packets (CHSP) applied for 5-10 min before catheterization
Number of subjects: 720
Study 29946873 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot compress with Chinese herbal salt packets (CHSP)
Number of subjects: 720
Study 29946873 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional catheterization and nursing care)
Number of subjects: 720
Study 26911315 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus 0.1% ointment
Number of subjects: 12
Study 26911315 — intervention group
Group type: COMPARATOR
Intervention: Polyunsaturated fatty acids (PUFA) lotion 12%
Number of subjects: 12
Study 24841184 — intervention group
Group type: EXPERIMENTAL
Intervention: Told‐NIC
Number of subjects: 51
Study 24841184 — intervention group
Group type: COMPARATOR
Intervention: Told‐DENIC
Number of subjects: 51
Study 22305830 — intervention group
Group type: EXPERIMENTAL
Intervention: RLX030 (recombinant form of human relaxin 2) 30 μg/kg per day IV infusion for 48 hours
Number of subjects: 1160
Study 22305830 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1160
Study 22305830 — intervention group
Group type: EXPERIMENTAL
Intervention: RLX030
Number of subjects: 1160
Study 20132129 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide infusion (30 ng (kg min)(‐1))
Number of subjects: 8
Study 20132129 — intervention group
Group type: COMPARATOR
Intervention: Control (sodium chloride infusion)
Number of subjects: 8
Study 18222389 — intervention group
Group type: EXPERIMENTAL
Intervention: Septic mice
Number of subjects: 13
Study 18222389 — intervention group
Group type: EXPERIMENTAL
Intervention: Septic patients
Number of subjects: 13
Study 16163679 — intervention group
Group type: EXPERIMENTAL
Intervention: Life Support Preferences Questionnaire (LSPQ)
Number of subjects: 0
Study 16163679 — intervention group
Group type: COMPARATOR
Intervention: Non-Hispanic patients
Number of subjects: 0
Study 16163679 — intervention group
Group type: COMPARATOR
Intervention: Hispanic patients
Number of subjects: 0
Study 12514144 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin (0.3 micro g x kg(‐1) infused intravenously over 20 min)
Number of subjects: 59